Karnataka pushes Centre to expand medicine price controls beyond cancer drugs

Karnataka's Health Minister U.T. Khader has urged the Centre to extend price rationalisation policies beyond cancer medications to encompass other expensive essential drugs that impose substantial financial burdens on patients across the state.

Khader emphasised that price regulation mechanisms must translate into tangible savings for patients rather than remaining merely regulatory frameworks. The state government's position reflects growing concerns about the affordability of critical medicines in India's healthcare system.

Currently, price controls apply to certain oncology drugs, but the Karnataka government argues that many other life-saving treatments remain prohibitively expensive for ordinary patients. The health minister's appeal underscores the tension between pharmaceutical industry interests and public health accessibility concerns.

The push from Karnataka adds to ongoing national debates about medicine pricing in India. Advocates contend that broader price controls could significantly reduce out-of-pocket healthcare expenses for patients requiring long-term treatment for serious conditions, though pharmaceutical manufacturers have traditionally opposed such measures citing concerns about profit margins and research investment.